Proteomics & Glyco-Proteomic Analysis of Follicular Fluid
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To the best of the investigators knowledge, exhaustive characterization of the low and high abundant proteins and glyco-proteins of the Follicular Fluid (FF) has not yet been achieved. Such an analysis may provide critical molecular data on the role of the FF in oocyte maturation and may identify specific changes in the FF proteome of patients with gynecologic problems, such as Polycystic Ovary Syndrome (PCOS).
Specific Aims
- To perform a comprehensive analysis of normal human FF using sensitive mass spectrometry in combination with conventional approaches for proteomic evaluation and using HPLC and Western blot for glyco-proteomic analysis.
- Characterize differential proteomic and glyco-proteomic patterns of the FF in normal women compared to lean and obese women with PCOS.
- To supplement the differential proteomic and glyco-proteomic analysis with steroid hormone analysis in all FF samples.
| Condition | Intervention |
|---|---|
|
Polycystic Ovary Syndrome Normal Volunteers |
Drug: IVF Antagonist Protocol |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Proteomics & Glyco-Proteomic Analysis of Follicular Fluid Derived From Health Patient/Donors and Polycystic Ovary Syndrome Patients |
- Proteomic analysis [ Time Frame: Participants will be followed for one IVF cycle including pregnancy outcomes, on average this will be 6-8 weeks. ] [ Designated as safety issue: No ]For proteomic analysis the follicular fluid samples will be either directly analyzed by MS or will be processed to deplete albumin which is likely to be present in very high abundance in the FF.
- Hormone analysis [ Time Frame: Participants will be followed for one IVF cycle including pregnancy outcomes, on average this will be 6-8 weeks. ] [ Designated as safety issue: No ]An aliquot of FF from each patient will be analyzed for the following steroid hormones: progesterone, 17-alpha-hydroxyprogesterone, androstenedione, testosterone, estradiol, and dihydrotestosterone.
Biospecimen Retention: Samples Without DNA
Follicular Fluid
| Estimated Enrollment: | 30 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | January 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Normal patients
Women with infertility diagnosis of male factor only or women who are oocyte donors
|
Drug: IVF Antagonist Protocol
|
|
Polycystic Ovary Syndrome, High BMI
Women with Polycystic Ovary Syndrome with a BMI between 30-35
|
Drug: IVF Antagonist Protocol
|
|
Polycystic Ovary Syndrome, Low BMI
Women with Polycustic Ovary Syndrom with a BMI between 20 & 25
|
Drug: IVF Antagonist Protocol
|
Detailed Description:
In this study, we plan to utilize ultrasensitive mass spectrometry (MS) and other conventional proteomic approaches to identify the low and high abundant proteins present in human FF. Additionally, we plan to use high-performance liquid chromatography (HPLC) and Western blot techniques to evaluate the Neu5Gc and glycan array based ELISA techniques to detect anti-Neu5Gc antibody profile in human FF. This analysis will be performed on FF samples obtained from normal women undergoing In-Vitro Fertilization and Embryo Transfers (IVF-ET) for a male factor alone and oocyte donors from our 3rd Party Reproduction Program and from lean and obese women with PCOS. This study will provide information on protein, glycoprotein, and steroid hormone expression during normal folliculogenesis and during the pathologic condition of PCOS, which should also provide basic scientific information on normal and abnormal oocyte development.
Human FF bathes the developing oocyte. Previous studies indicate that the FF contains cytokines, steroidal and protein hormones, and growth factors. The presence of proteins with such significant biological properties implies a paracrine and autocrine role for the FF in promoting normal oocyte development. Furthermore, the presence of any antigenic sialic acid Neu5Gc and the presence of antibodies targeting these antigenic glycoconjugates (glycolipid and glycoproteins decorated with sialic acid) may interfere with oocyte development, hormonal expression, fertilization, and possibly implantation. Here we hypothesize that an exhaustive proteomic and glyco-proteomic characterization of human FF is essential for a thorough understanding of its biological significance. We also hypothesize that PCOS may have differential expression of the FF protein and glyco-protein milieu, and that the expression may differ further between lean and obese women with PCOS. PCOS represents a heterogeneous disorder. The severity of hyperandrogensim, metabolic and menstrual disturbance, and obesity is variable with up to 40% not clinically expressing signs of classic hyperandrogenism. On the other hand, these atypical, often lean, PCOS women can have impaired glucose tolerance and diabetes. Reports suggest that these lean PCOS women have altered serum IGFBP-1, a characteristic endocrine feature of patients with obese PCOS, and related to hyperinsulinemia and/or obesity. The lean phenotype of PCOS and its significance is unclear but may represent a cryptic or unexpressed form of PCOS or may be a prelude to individuals who will later manifest clinical signs of obese/overweight PCOS. Changes in expression may be expected because of the different amounts of steroidal hormones and inflammatory markers in the FF derived from women with PCOS.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Women undergoing In Vitro Fertilization who have:
- male factor only infertility diagnosis or are oocyte donors
- PCOS
Inclusion criteria: Inclusion Criteria All
- Female patients undergoing controlled ovarian hyperstimulation (COH), transvaginal oocyte aspiration (TVA), and Saline Infused Sonography (SIS) with UL collection
- Age <35 y/o at time of in vitro fertilization (IVF) cycle
- Normal ovarian function defined Day 3 Follicular Stimulating Hormone (FSH) <8 pg/ml or Anti-Mullerian Hormone (≥ 1.0 ng/ml)
Inclusion Criteria Controls:
- Female patients undergoing COH and TVA donating her oocytes
- Female patients undergoing COH and TVA for male factor infertility only (i.e. no female causes of infertility)
- Normal menstrual cycles
Inclusion Criteria Lean PCOS:
- Diagnosis of PCOS by Rotterdam Criteria
- BMI ≤ 25 kg/m2 Inclusion Criteria Classic PCOS
1. Diagnosis of PCOS by Rotterdam Criteria 2. BMI > 30 kg/m2
Exclusion criteria:
- Age ≥ 35 y/o
- Female partners with infertility associated diagnosis (i.e. tubal factor, cervical factor, endometriosis)
- Unexplained infertility
Contacts and Locations| Contact: Steven Lindheim, MD, MMM | 513-585-0063 | steven.lindheim@uc.edu |
| Contact: Julie Sroga, MD | 513-585-2355 | julie.sroga@uc.edu |
| United States, Ohio | |
| Center for Reproductive Health | Not yet recruiting |
| Cincinnati, Ohio, United States, 45219 | |
| Contact: Steven Lindheim, MD, MMM 513-585-0063 steven.lindheim@uc.edu | |
| Contact: Julie Sroga, MD 513-585-2355 julie.sroga@uc.edu | |
| Principal Investigator: Steven Lindheim, MD,MMM | |
| Principal Investigator: | Steven Lindheim, MD, MMM | University of Cincinnati |
More Information
Publications:
| Responsible Party: | Steven Lindheim, Professor, University of Cincinnati |
| ClinicalTrials.gov Identifier: | NCT01487486 History of Changes |
| Other Study ID Numbers: | Proteomics of FF in PCOS |
| Study First Received: | November 16, 2011 |
| Last Updated: | December 5, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Cincinnati:
|
Polycystic Ovary Syndrome PCOS Follicular Fluid Proteomics Glyco-proteomics |
Additional relevant MeSH terms:
|
Polycystic Ovary Syndrome Ovarian Cysts Cysts Neoplasms Ovarian Diseases |
Adnexal Diseases Genital Diseases, Female Gonadal Disorders Endocrine System Diseases |
ClinicalTrials.gov processed this record on June 18, 2013